Original Article

Increased prostate cancer specific mortality following radical prostatectomy in men presenting with voiding symptoms—A whole of population study

Anthony D. Ta 1, Nathan P. Papa 1, 2, Nathan Lawrentschuk 1, 3, 4, *, Jeremy L. Millar 5, Rodney Syme 1, Graham G. Giles 2, Damien M. Bolton 1, **

1 Department of Surgery, Austin Hospital, University of Melbourne, Melbourne, Australia
2 Cancer Epidemiology Centre, Cancer Council Victoria, Melbourne, Australia
3 Olivia Newton-John Cancer Research Institute, Austin Hospital, Melbourne, Australia
4 Department of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
5 William Buckland Centre, The Alfred Hospital, Melbourne, Australia

Article history:
Received 26 April 2015
Accepted 4 June 2015
Available online 17 July 2015

Keywords:
Mortality
Prostate tumor
Surgery
Symptomatic
Whole of population

ABSTRACT

Background: Whole of population studies reporting long-term outcomes following radical prostatectomy (RP) are scarce. We aimed to evaluate the long-term outcomes in men with prostate cancer (PC) treated with RP in a whole of population cohort. A secondary objective was to evaluate the influence of mode of presentation on PC specific mortality (PCSM).

Methods: A prospective database of all cases of RP performed in Victoria, Australia between 1995 and 2000 was established within the Victorian Cancer Registry. Specimen histopathology reports and prostate-specific antigen (PSA) values were obtained by record linkage to pathology laboratories. Mode of presentation was recorded as either PSA screened (PSA testing offered in absence of voiding symptoms) or symptomatic (diagnosis of PC following presentation with voiding symptoms). Multivariate Cox and competing risk regression models were fitted to analyze all-cause mortality, biochemical recurrence, and PCSM.

Results: Between 1995 and 2000, 2,154 men underwent RP in Victoria. During median follow up of 10.2 years (range 0.26–13.5 years), 74 men died from PC. In addition to Gleason score and pathological stage, symptomatic presentation was associated with PCSM. After adjusting for stage and PSA, no difference in PCSM was found between men with Gleason score 3+4 and Gleason score 3+4. Men with Gleason score 4+3 had significantly greater cumulative incidence of PCSM compared with men with Gleason score 3+4.

Conclusions: Primary Gleason pattern in Gleason 7 PC is an important prognosticator of survival. Our findings suggest that concomitant voiding symptoms should be considered in the work-up and treatment of PC.

Introduction

Prostate cancer (PC) is the most commonly diagnosed male malignancy and the second most common cause of cancer-related death in Australia, and its incidence continues to increase in the Asia-Pacific region.1,2 The use of open radical prostatectomy (RP) for the surgical management of localized PC increased dramatically during the 1990s subsequent to the increasing use of prostate-specific antigen (PSA) testing and improved operative techniques.3–5 In more recent years, advances in laparoscopic and robotic surgery have seen a significant fall in rates of open surgery for PC.6 Due to the relatively recent uptake of robotic surgery, long-term survival data following surgery for PC is largely limited to open RP series.

PC is associated with a long natural history. Multiple studies of long-term follow-up data in patients managed with observation and surgery have been published, although few of these represent...
whole of population series. Lower PC specific mortality (PCSM) observed in men with more low-risk disease has resulted in a shift towards increased use of active surveillance. Conversely, men with higher risk PC may have the greatest survival benefit from surgery, as those with aggressive disease may be cured by RP alone or as part of multimodality treatment.

Presentation in men with PC is usually asymptomatic and based on serum PSA, however, there is a subgroup of men presenting with lower urinary tract symptoms (LUTS) who potentially harbor a malignancy.

In this study, we evaluate the long-term survival outcomes in a prospective whole of population study of men treated with RP in the PSA era. Furthermore, we sought to identify the impact on PCSM of symptomatic presentation with voiding dysfunction leading to cancer diagnosis, as opposed to diagnosis based purely on PSA testing.

Materials and methods

Patient population

The Victorian Radical Prostatectomy Registry is a prospective whole of population series of men who underwent RP for the treatment of clinically localized prostate adenocarcinoma between 1995 and 2000 in Victoria, Australia. This database was established within the Victorian Cancer Registry, which documents all cancer cases in the state, excluding nonmelanoma skin cancer, and is managed by the Cancer Council Victoria. Further details regarding patient registration and data collection have previously been published.

Clinical and histopathological details

The mode of presentation was recorded at registration as either PSA screened (PSA testing offered by a urologist or general practitioner in the absence of significant voiding symptoms), symptomatic, or other. Symptomatic presentation was defined as patients who sought treatment for irritative or obstructive symptoms and were subsequently diagnosed with PC. Specimen histopathology reports, and pre- and post-RP PSA surveillance values were obtained by record linkage to pathology laboratories. Biochemical recurrence (BCR) post-RP was defined as two consecutive PSA values ≥ 0.2 ng/mL and the latter date taken as the time of recurrence. Deaths were recorded by the Victorian Cancer Registry as either death from PC, death from another cancer, or death from another cause. Men who received neoadjuvant therapy were excluded from all analyses.

Statistical analysis

Multivariate Cox proportional hazards models were fitted to analyze all-cause mortality and time to BCR. Competing risks regression based on the Fine and Gray model, with other cause mortality (PCSM) was used to analyze cumulative incidence plots. In all regressions, time from surgery was used as the time axis and all covariates were entered into the model simultaneously. Formal statistical testing of the proportional hazards assumption in the Cox models using Schoenfeld residuals found that it was not violated. Proportionality was assessed in the competing risks regression by including interactions with a time variable for all covariates and these were found to be nonsignificant. In the symptomatic subgroup analysis, age at surgery and PSA were found to be not normally distributed by the skewness-kurtosis test and hence were compared with the Wilcoxon rank sum test. Grade and stage were compared using the Kruskal-Wallis test. All tests were two sided and significance level was set at $P \leq 0.05$.

Analyses were performed using Stata 12.1 SE (Statacorp, College Station, TX, USA).

Results

The full registry comprises 2,154 patients. Baseline characteristics are shown in Table 1. A total of 2,112 individuals had follow-up data available (98.1%). After excluding men who received neoadjuvant therapy, 1,935 individuals had data available including grade, stage, and PSA. These men constitute the population set analyzed in this report. During a median follow up of 10.2 years (range 0.26–13.5 years), 622 men experienced BCR and 233 men died, including 74 from PC.

Results of the multivariate Cox regression analysis used to model risk of BCR, all-cause mortality, and PCSM are shown in Table 2. Increasing Gleason grade and tumor stage were strongly associated with time to BCR and PCSM. The nonsignificant result for pT4 tumors in all-cause mortality was likely due to the small number of events in this series. A higher baseline PSA was associated with reduced time to BCR, but was not found to be predictive of PCSM or overall mortality. Older age at surgery predicted time to all-cause mortality but not PCSM.

Symptomatic presentation with subsequent diagnosis of PC was significantly associated with older age and higher PSA, grade, and stage as shown in Table 3. After multivariate adjustment of these clinicopathologic parameters, there was still an association between symptomatic presentation and time to PCSM ($P = 0.036$, Fig. 1).

There were 16 PC-specific deaths observed in men who had Gleason score ≤ 6 disease and 14 in men with Gleason score 3 + 4 = 7 disease. After adjusting for pathological stage, PCSM outcomes for Gleason score ≤ 6 and 3 + 4 tumors did not significantly differ ($P = 0.231$, Fig. 2). In a low risk subgroup of men with PSA ≤ 10 ng/mL and pT1/T2 stage ($n = 994$, 51.4%), 17 PC deaths were observed overall, including 11 and four men with Gleason score ≤ 6 and 3 + 4, respectively. Similarly, no significant difference in PCSM was observed between the two groups ($P = 0.649$), although the number of events was small (Fig. 3).

In the subgroup of men with Gleason 7 tumors ($n = 674$), 35 deaths were observed, including 14 and 21 in men with Gleason score ≤ 6 and 3 + 4, respectively.

| Table 1 Baseline characteristics. | Median (mean) | Range |
|----------------------------------|---------------|-------|
| Age at surgery (yr) | 61.9 (61.4) | 38.9–81.7 |
| PSA (ng/mL) | 8.4 (10.2) | 0–112 |
| Gleason grade | | |
| $n$ | % |
| 2–6 | 1,123 | 58.1 |
| 7 (3 + 4) | 489 | 25.3 |
| 7 (4 + 3) | 185 | 9.6 |
| 8–10 | 135 | 7.0 |
| Pathological stage | | |
| $n$ | % |
| T1/T2 | 1,437 | 74.4 |
| T3a | 294 | 15.2 |
| T3b | 160 | 8.3 |
| T4 | 41 | 2.1 |
| Mode of presentation | | |
| $n$ | % |
| Symptomatic | 631 | 32.7 |
| Nonsymptomatic | 1,301 | 67.3 |
| Urologist | (206) | (15.8) |
| GP screen | (1,095) | (84.2) |

GP, general practitioner; PSA, prostate-specific antigen.
Table 2
Multivariate cox regression analysis.

|                        | Biochemical recurrence | All-cause mortality | Prostate cancer-specific mortality |
|------------------------|------------------------|---------------------|-----------------------------------|
|                        | n  | HR (95% CI)  | p       | n  | HR (95% CI)  | p       | n  | HR (95% CI)  | p       |
| Baseline characteristics|    |             |        |    |             |        |    |             |        |
| Symptomatic (vs. not)  | 215| 1.06 (0.90–1.25) | 0.481 | 101| 1.34 (1.03–1.74) | 0.029 | 37| 1.64 (1.04–2.60) | 0.034 |
| Age (yr)               | –  | 1.00 (0.99–1.01) | 0.997 | –  | 1.07 (1.04–1.09) | <0.001 | –  | 0.99 (0.95–1.03) | 0.514 |
| PSA (per 5 ng/mL)      | –  | 1.09 (1.05–1.12) | <0.001 | –  | 1.01 (0.94–1.07) | 0.862 | –  | 1.00 (0.90–1.10) | 0.950 |
| Gleason score          |    |             |        |    |             |        |    |             |        |
| < 6 (reference group)  | 245|             |        | 104|             |        | 16|             |        |
| 7 (3+4)                | 203| 1.90 (1.57–2.30) | <0.001 | 52| 1.08 (0.77–1.52) | 0.665 | 14| 1.61 (0.79–3.30) | 0.194 |
| 7 (4+3)                | 96 | 2.34 (1.83–3.01) | <0.001 | 37| 1.72 (1.15–2.58) | 0.008 | 21| 4.75 (2.45–9.22) | <0.001 |
| 8–10                   | 78 | 2.24 (1.69–2.98) | <0.001 | 40| 2.36 (1.55–3.60) | <0.001 | 23| 5.39 (2.61–11.11) | <0.001 |
| Pathological stage     |    |             |        |    |             |        |    |             |        |
| T1/T2 (reference group)| 369|             |        | 139|             |        | 23|             |        |
| T3a                    | 123| 1.35 (1.09–1.67) | 0.006 | 38| 1.15 (0.79–1.66) | 0.478 | 16| 2.37 (1.23–4.55) | 0.010 |
| T3b                    | 107| 2.36 (1.86–2.98) | <0.001 | 49| 2.25 (1.54–3.30) | <0.001 | 31| 5.83 (3.18–10.69) | <0.001 |
| T4                     | 23 | 2.03 (1.29–3.19) | 0.002 | 7 | 1.58 (0.73–3.42) | 0.245 | 4 | 5.15 (1.88–14.06) | 0.001 |

CI, confidence interval; HR, hazard ratio; PSA, prostate-specific antigen; SHR, subhazard ratio.

Table 3
Comparison of symptomatic versus nonsymptomatic men.

|                          | Symptomatic Median (mean) | Nonsymptomatic Median (mean) | P (for difference) |
|--------------------------|---------------------------|-----------------------------|-------------------|
| Age (yr), median (mean)  | 62.78 (62.09)             | 61.66 (61.06)               | <0.001            |
| PSA (ng/mL), median (mean)| 7.9 (10.36)               | 8.2 (10.19)                | 0.017             |
| Gleason Score            |                           |                             |                   |
| < 6 (reference group)    |                           |                             |                   |
| 7 (3+4)                  | 374 (59.3)                | 749 (57.6)                 | 0.038             |
| 7 (4+3)                  | 138 (21.9)                | 351 (27.0)                 | –                 |
| 8–10                     | 65 (10.3)                 | 120 (9.2)                  | –                 |
| Pathological stage       |                           |                             |                   |
| T1/T2 (reference group)  | 455 (72.1)                | 982 (75.5)                 | 0.023             |
| T3a                      | 91 (14.4)                 | 203 (15.6)                 | –                 |
| T3b                      | 68 (10.8)                 | 92 (7.1)                   | –                 |
| T4                       | 17 (2.7)                  | 24 (1.8)                   | –                 |

Data are presented as n (%) unless otherwise indicated.

PSA, prostate-specific antigen.

Discussion

This study represents the largest reported whole of population cohort of men treated with RP with >10-years follow up. Although evaluating the role of screening was not a primary endpoint in this study, we found that in addition to previously demonstrated pathologic predictors of PCSM, mode of presentation influenced survival outcomes. We report a difference in survival between men who were diagnosed with PC following PSA testing offered by their family doctor or urologist, compared with men who had diagnosis of PC made following a presentation with symptoms of urinary obstruction.

Symptomatic presentation was associated with older age and higher PSA, grade, and stage, however, even after adjustment for

![Fig. 1. Symptomatic presentation and prostate cancer-specific mortality. 4) After adjustment for age, PSA, grade and stage. PSA, prostate-specific antigen; SHR, subhazard ratio.](image1)

![Fig. 2. Comparison of Gleason score ≤ 6 and 7 (3+4). 5) After adjustment for stage. SHR, subhazard ratio.](image2)
these parameters, there was an association between symptomatic presentation and reduced time to PCSM. Minimal data studying this parameter has been published to date, possibly because this variable is less commonly noted now that most PC is PSA detected in North America and Europe. Data from The Swedish National Prostate Cancer Register has shown that most men with PC diagnosed after a health check-up, compared with men presenting with LUTS, have localized tumors of low or intermediate risk.20 Lee et al19 after a health check-up, compared with men presenting with LUTS, have localized tumors of low or intermediate risk.

We found that the subgroup of men with Gleason 7 PC had heterogeneous outcomes. It has been previously shown that primary Gleason pattern 4 in men with Gleason 7 PC is associated with greater BCR following surgery compared with primary Gleason score 3.23–26 However, the effect of primary Gleason pattern 4 on mortality outcomes in these men is less clear. Among men with Gleason 3 + 4 and 4 + 3 PC, Eggener et al16 found no difference in 15-year PCSM in >20,000 men treated with RP at multiple large US institutions. Conversely, Wright et al27 demonstrated higher rates of BCR and PCSM in men with Gleason score 4 + 3 compared with men with Gleason score 3 + 4 in a population-based cohort of men with Gleason 7 PC and median 13-year follow up, although the study was limited to 753 men from a single county under the age of 65 years. Stark et al28 similarly demonstrated a threefold increase in PCSM in men with Gleason score 4 + 3 compared with men with Gleason score 3 + 4 with 20-year follow up, however, the analysis did not control for PSA or tumor stage. Furthermore, the study was limited to 693 RP specimens and all men were identified from health survey studies conducted on health professionals.

This heterogeneity in outcomes in men with Gleason 7 PC in our study may further be explained by tumor volume. A trend between increasing tumor volume and adverse pathological findings at RP was noted, but was not reported, as tumor volume was not available for all men. It is possible that the presence of primary Gleason pattern 4 is associated with increased tumor volume, and this requires further evaluation. Nonetheless, the distinctions between the predominant Gleason patterns remain important. We confirm in a whole of population setting that amongst men with Gleason 7 PC treated with RP, primary Gleason pattern 4 confers significantly greater PCSM compared with primary Gleason pattern 3.

Some limitations of this study include potentially incomplete data regarding adjuvant or salvage radiation therapy, and an inability to comment on functional or quality of life measures, which are important outcomes following RP. Prostate volume and tumor volume data were also not available for all men. However, this prospective study represents a statewide whole of population register of RP performed by all urologists of varying experience in large tertiary and smaller community hospitals. By including men of varying pathology, socioeconomic status, and residency, and all urologists undertaking RP regardless of their experience or surgical volume, this study is representative of long-term outcomes on a population and community level that may not be reflected in large series from high-volume institutions from the US and Europe.
Conclusion

In this whole-of-population based study, there appears to be increased PCSM for men treated by RP for clinically localized disease where their presentation was with symptomatic voiding difficulty, in comparison with men who had their cancer diagnosed on the basis of PSA elevation alone. This finding should be considered in determining the most appropriate form of treatment for individual patients, including where active surveillance may be an option. Furthermore, Gleason score $3 + 4 = 7\text{ PC}$ has been shown in this whole-population series to have significantly less PCSM than Gleason score $4 + 3 = 7\text{ disease}$, and similar to that of Gleason score 6 disease, reinforcing the significance of this pathologic distinction.

Conflicts of interest

All contributing authors declare no conflicts of interest

Acknowledgments

We want to thank participating urologists for their valuable contribution to the Victorian Radical Prostatectomy Registry. Initial funding for this project was obtained from a grant in aid from Esso Australia. Ongoing support and infrastructure has been provided by The Cancer Council of Victoria and by the Whitten Foundation

References

1. Baade PD, Youlten DR, Cramb SM, Dunn J, Gardiner RA. Epidemiology of prostate cancer in the Asia-Pacific region. Prostate Int 2013;1:47–58.
2. Thursfield V, Farrugia H, Robertson P, Giles G. Cancer in Victoria: statistics and trends 2013 [Internet]. 2014 [cited 2014 Feb]. Available from: http://www.cancervic.org.au/downloads/cec/cancer-in-vic/CCV-statistics-trends-2013.pdf.
3. Bolton D, Sevi H, Millar J, Kelsall H, Davidson A-J, Smith C, et al. A whole of population-based series of radical prostatectomy in Victoria, 1995 to 2000. Aust N Z J Public Health 2009;33:527–33.
4. Catalana WJ, Carvalhal GF, Mager DE, Smith DS. Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies. J Urol 1999;162:433–8.
5. Walsh PC, Donker PJ. Impotence following radical prostatectomy: insight into etiology and prevention. 1982. J Urol 2002;167(2 Pt 2):1005–10.
6. Lowrance WT, Eastham JA, Savage C, Maschino AC, Laudone VP, Dechet CB, et al. Contemporary open and robotic radical prostatectomy practice patterns among urologists in the United States. J Urol 2012;187:2067–92.
7. Albertson PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005;293:2095–101.
8. Johansson JE, Andrei O, Andersson SD, Dickman PW, Holmberg L, Magnusson A, et al. Natural history of early, localized prostate cancer. JAMA 2004;291:2713–9.
9. Bill-Axelson A, Holmberg L, Ruutu M, Garino H, Stark JR, Busch C, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2011;364:1708–17.
10. Eggener SE, Scardino PT, Walsh PC, Han M, Partin AW, Trock BJ, et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol 2011;185:969–75.
11. Isbarn H, Wanner M, Salomon G, Steuber T, Schloott M, Kollerlann J, et al. Long-term data on the survival of patients with prostate cancer treated with radical prostatectomy in the prostate-specific antigen era. BJU Int 2010;106:37–43.
12. Porter CR, Kodama K, Gibbons RP, Correa JR, Chun FK, Perrotte P, et al. 25-year prostate cancer control and survival outcomes: a 40-year radical prostaticctomy single institution series. J Urol 2006;176:569–74.
13. Roehl KA, Han M, Ramos CG, Antener JAV, Catalana WJ. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 2004;172:910–4.
14. Godman RA, Holmberg E, Khatami A, Stranne J, Hugosson J. Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Goteborg randomised population-based prostate cancer screening trial. Eur Urol 2013;63:101–7.
15. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Lobjaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010;28:126–31.
16. Stattin P, Holmberg E, Johansson JE, Holmberg L, Adolfsen J, Hugosson J, et al. Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study. J Natl Cancer Inst 2010;102:950–8.
17. Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012;367:203–13.
18. Chung BH. The role of radical prostatectomy in high-risk prostate cancer. Prostate Int 2013;1:95–101.
19. Lee DH, Lee SH, Lee DH, Chung MS, Chung BH. Are men who undergo radical prostatectomy with lower urinary tract symptoms at an increased risk for aggressive prostate cancer? Korean J Urol 2011;52:819–23.
20. Bratt O, Berglund A, Adolfsen J, Johansson J-E, Tornblom M, Stattn P, et al. Prostate cancer diagnosed after prostate-specific antigen testing of men without clinical signs of the disease: a population-based study from the National Prostate Cancer Register of Sweden. Scand J Urol Nephrol 2010;44:384–90.
21. Lavery HJ, Droller MJ. Do Gleason patterns 3 and 4 prostate cancer represent separate disease states? J Urol 2012;188:1667–75.
22. Ross HM, Kryvenko ON, Cowan JE, Simko JP, Wheeler TM, Epstein JL. Do adenocarcinomas of the prostate with Gleason score (GS) ≤ 6 have the potential to metastasize to lymph nodes? Am J Surg Pathol 2012;36:1346–52.
23. Alenda O, Ploussard G, Mourracade P, Xylinas E, de la Taille A, Allery Y, et al. Impact of the primary Gleason pattern on biochemical recurrence-free survival after radical prostatectomy: a single-center cohort of 1,248 patients with Gleason 7 tumors. World J Urol 2011;29:671–6.
24. Chan TY, Partin AW, Walsh PC, Epstein JL. Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 at radical prostatectomy. Urology 2000;56:823–7.
25. Khodadami SM, Shariat SF, Lotan Y, Saboorian H, McConnell JD, Sagalowsky AI, et al. Predictive value of primary Gleason pattern 4 in patients with Gleason score 7 tumours treated with radical prostatectomy. BJU Int 2004;94:42–6.
26. Ro YK, Lee S, Jeong CW, Hong SK, Byun SS, Lee SE. Biochemical recurrence in Gleason score 7 prostate cancer in Korean men: significance of the primary Gleason grade. Korean J Urol 2012;53:826–9.
27. Wright JL, Salinas CA, Lin DW, Kolb S, Koopmeiners J, Feng Z, et al. Prostate cancer specific mortality and Gleason 7 disease differences in prostate cancer outcomes between cases with Gleason 4 + 3 and Gleason 3 + 4 tumors in a population based cohort. J Urol 2009;182:2702–7.
28. Stark JR, Perner S, Stampfer MJ, Sinnott JA, Finn S, Eisenstein AS, et al. Gleason score and lethal prostate cancer: does $3 + 4 + 5 = 7$? J Clin Oncol 2009;27:3459–64.
